Amdinocillin Market

The amdinocillin market was valued at USD132.0Mn by 2019. As per the latest research citings provided by the World Health Organization (WHO) annually, it is estimated that urinary tract infection affects 150 million people throughout the globe. The constant rise in the reported cases of typhoid infections in the developing regions further accentuates the amdinocillin market growth.

Amdinocillinis classified as an extended-spectrum penicillin antibiotic that binds to the penicillin-binding protein 2 and exerts its therapeutic efficacy against gram-negative bacteria in diseases such as urinary tract infection, typhoid, pyelonephritis, etc. The oral bioavailability of amdinocillin is very low hence its prodrug pivmecillinam is prescribed for the treatment of infections occurring due to gram-negative bacteria.

The major segments related to the amdinocillin market are:

By Treatment (2017–2027; US$ Mn)

Urinary Tract Infection

Typhoid

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global amdinocillin market
• The overall segmentation of the amdinocillin market, by treatment, distribution channel, and geography is minutely studied. Urinary tract infection and hospital pharmacy are dominating the treatment and distribution channel segments respectively
• The constant rise in the number of reported cases of complicated urinary tract infection caused by multidrug resistance pathogens
• Promising clinical trial investigation pertaining to the therapeutic efficacy and safety of amdinocillin in the treatment of pyelonephritis

Report gist?

• The study of the global amdinocillin market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of treatment and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
• The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

• This study is suitable for industry participants and stakeholders in the biopharmaceutical companies engaged in manufacturing amdinocillin drugs and prodrug for the treatment of complicated urinary tract infection occurring due to multidrug-resistant pathogens
• The report will benefit researchers engaged in the clinical trial investigation to test the therapeutic application of amdinocillin prodrug in the treatment of pyelonephritis
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to amdinocillin market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Urinary tract infections are presently representing the largest market share in the treatment segment for the amdinocillin market. It is usually caused by gram-negative bacteria such as E.coli, Klebsiella, Candida, Proteus, etc. According to the latest statistics provided by the World Health Organization (WHO), the urinary tract infection has a lifetime incidence rate of 50−60% in adult women. Typhoid fever is endemic in developing regions such as Asia, Africa, Latin America, etc, according to the research findings provided by the World Health Organization (WHO), it is estimated to infect 21.6 million people annually worldwide. It is caused by the gram-negative bacteria Salmonella Typhi. The other treatment segment is anticipated to be the fastest-growing segment in the near future on account of promising clinical trial studies pertaining to the therapeutic efficacy and safety of amdinocillin in the treatment of pyelonephritis.

Hospital pharmacy is currently dominating the distribution channel segment for the amdinocillin market. Amdinocillin is an extended-spectrum penicillin antibiotic that is associated with drug-related adverse events, hence hospital pharmacist ensures precise safety pertaining to drug compounding according to doctor’s prescription. Retail pharmacy is gaining huge popularity in developing countries on account of flourishing generic drugs market and proactive government intervention in establishing generic retail pharmacy stores to provide medicines at low cost to the poor and needy patients.

Europe is currently holding the largest market share in the geography segment for the amdinocillin market. The rising prevalence of healthcare-associated urinary tract infection (HAUTI) primarily drives the market growth in the region. As per the latest research citings brought forward by the National Institute of Health (NIH), the prevalence rate of HAUTI in the European region is 19.6%. Furthermore, a proactive role adopted by the European Medical Agency (EMA) to evaluate the clinical trial investigation of amdinocillin prodrug I the treatment of pyelonephritis will further propel the market growth. Domicile of major players in the region such as Leo Pharma, Karo Pharma AB, Orion Pharma AB, etc. further accentuate the market growth in the region. The market growth in the Asia Pacific region is attributed to key factors such as the rising prevalence of complicated urinary tract infection in the female population and the existence of a well-established generic drug market. North America is anticipated to register rapid market growth during the forecast period because recently the USFDA has granted Qualified Infectious Disease Product (QIDP) designation to amdinocillin for the treatment of complicated urinary tract infection prevalence in the region.